CRF Research Efforts

The Choroideremia Research Foundation (CRF) has provided over $4 million in research grants to help find treatment options and a cure for Choroideremia (CHM).

If you are interested in applying for funding, please visit: .

View list of grants awarded

Clinical Trials

While there is no treatment or cure for Choroideremia, there are clinical trials underway testing potential treatments for CHM. Individuals interested in being part of a clinical trial or being treated for CHM when a treatment or cure becomes available will need to have had a genetic test to confirm their diagnosis of Choroideremia. Please visit for more information. 

Please note that any information regarding clinical trials or genetic testing is provided for informational purposes only. The Choroideremia Research Foundation does not endorse any specific company, clinical trial or genetic test. Please discuss any questions you may have with your healthcare provider.

A number of clinical trials and natural history studies for Choroideremia are currently available and listed on the National Institutes of Health’s website.

National Institutes of Health logo


Click here for basic information on clinical trials.

Click here for information for patients and families.



Click here to visit the National Center for Biotechnology Information’s website and view a comprehensive list of companies worldwide which offer genetic testing for choroideremia.

CHM Evolving Therapies

Gene Therapy

Genetic diseases like choroideremia are caused by a mutation, or defect, in the body’s DNA.  These genetic mutations prevent the body from producing a beneficial protein necessary for certain cells to survive.  Gene therapy is a type of treatment for genetic diseases in which the normal gene is delivered into the affected cells, enabling the cells to produce this protein and restore normal cellular function.

Scientists have tapped into the ability of viruses, like the common cold virus, to penetrate into the cells in the human body. Certain viruses have been modified to prevent them from causing disease in people while still maintaining their ability to enter into cells. These modified viruses, called vectors, have been engineered to carry a normal copy of the choroideremia gene into the body’s cells and restore their normal function and health. Gene therapy for choroideremia is delivered through an injection into the back of the eye to provide the vector directly to the affected cells. Clinical trials are ongoing to test the safety and the effectiveness of gene therapy for treating choroideremia patients.

Stem Cell Research

Stem cells are referred to as progenitor cells, which means they can develop into almost all other cells in the body.  Historically, stem cells were only obtained from embryos which created significant controversy. Recent developments, however, have enabled scientists to take a blood or skin sample from an individual and create stem cells from these tissue samples. These stem cells, referred to as Induced Pluripotent Stem Cells, or iPSC’s, can then be influenced to evolve into other cell types in the body by following specific scientific protocols.  With these techniques, scientists can use iPSC cells to create specific retinal cells, called photoreceptors and retinal pigment epithelium (RPE) cells, which are the cell types lost in choroideremia. Scientists are working to organize these iPSC-derived photoreceptors and RPE cells into transplant patches which could be used to replace areas of vision loss.

By creating iPSC’s cells from choroideremia patients, scientists can study the disease and learn more about its progression at a microscopic level. This information can help scientists to better understand the patient history of choroideremia in conjunction with tests done at the doctor’s office. In addition, future treatments can be tested on these iPSC’s cells rather than on animal models of choroideremia which may not respond in the same way as humans.

Pharmacological Therapy

Scientists are working to develop and test medications which can slow down or stop the progression of vision loss.

The genetic defect in choroideremia causes specific cells in the retina to gradually stop functioning normally. Eventually these cells die off, causing vision loss. Scientists are researching different types of compounds called neuroprotective agents that can improve the health of the retina by keeping these affected cells functioning and surviving longer, thereby slowing the progression of vision loss. Another area of research involves a type of experimental medication called read-through agents. These medications are specifically designed to treat certain types of gene mutations called nonsense mutations, which interrupt the production of the choroideremia protein causing it to be too short and not function. Read-through agents convince the body’s machinery to ignore this genetic “stop sign” and produce the full-length protein, which enables normal function to affected cells. Read-through agents are being tested in clinical trials for other diseases like Duchenne’s Muscular Dystrophy and Cystic Fibrosis.

Retinal Prosthetics

Retinal prosthetics research is underway which may be able to provide an alternative to natural vision.

While users will not regain sight as most people know it, the technology offers the ability to distinguish and interpret light patterns, recognize outlines of basic shapes, people and movement, and improve the ability to navigate more independently throughout the world.

Research BioBank

In 2014, CRF established a Choroideremia BioBank in order to expedite CHM research globally with readily accessible CHM cellular samples for preclinical research. Coriell Institute’s NIGMS Human Genetic Cell Repository houses these CHM lines, all of which have passed their stringent verification and quality control protocols. The CHM lines include iPSC, fibroblasts, DNA, LCL and skin.

Access to these cell lines in the CHM BioBank are via For a listing of the CHM cell lines click the button below.

CHM Cell Line Listing

WiCell also has select Choroideremia (hiPSC) available: Click the button below for cell lines.

Additional CHM Cell Lines

Other Research Resources

Visit Google Scholar

Google Scholar provides a simple way to broadly search for scholarly literature.

Visit PubMed

PubMed comprises citations for biomedical literature, life science journals, and online books.

Apply for Funding

Our objective is finding a cure or effective treatment for choroideremia.

Accomplishing this goal relies on:

  • Research that provides essential resources and knowledge for the field (e.g. model systems, understanding genetic underpinnings, annotated patient specimens)
  • Innovative research that opens new pathways for diagnosis and drug discovery
  • Promising projects that are less likely to get traditional funding such as:
    • Seed funding for hypothesis-generating projects
    • High quality projects proposed by young investigators
    • Foundational projects with an important but long-term payoff

If you are interested in submitting a request for funding please format your application as specified in the Grant Application Guidelines.  Applications are accepted on a rolling basis and should be submitted to both Kathi Wagner, Executive Director, and Jess Thompson, MD, Research Committee Chair.

Science Advisory Board

Ian MacDonald, MD Headshot

Ian MacDonald, MD (chair) Professor, Department of Medical Genetics, University of Alberta Edmonton, Alberta, Canada

Tomas Aleman, MD headshot

Tomas Aleman, MD Associate Professor of Ophthalmology at the Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania Philadelphia, Pennsylvania

Kapil Bharti, PhD headshot

Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Unit, National Institutes of Health, Intramural Research Program Bethesda, Massachusetts

Sanford Boye, MS headshot

Sanford Boye, MS Associate Scientist, Department of Ophthalmology, Shannon E. Boye Laboratory, University of Florida Health Gainesville, Florida

Shannon Boye, PhD headshot

Shannon Boye, PhD Associate Professor, Department of Ophthalmology, Shannon E. Boye Laboratory, University of Florida Health Gainesville, Florida

Frans Cremers, PhD headshot

Frans Cremers, PhD Professor, Ophthalmogenetics, Department of Human Genetics and Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center Nijmegen, Netherlands

Jacque Duncan, MD headshot

Jacque Duncan, MD Professor in Ophthalmology, University of California San Francisco San Francisco, California

Rachel Huckfeldt, MD, PhD headshot

Rachel Huckfeldt, MD, PhD Associate Surgeon and Director, Inherited Retinal Degenerations Fellowship, Massachusetts Eye and Ear; Assistant Professor of Ophthalmology, Harvard Medical School Boston, Massachusetts

Alex Iannaccone, MD, MS, FARVO headshot

Alex Iannaccone, MD, MS, FARVO Director, Center for Retinal Degenerations and Ophthalmic Genetic Diseases, and Professor, Ophthalmology, Duke University Department of Ophthalmology Durham, North Carolina

Mark Pennesi, MD, PhD headshot

Mark Pennesi, MD, PhD Assistant Professor in Ophthalmic Genetics, Oregon Health and Science University (OHSU) Casey Eye Institute Portland, Oregon

Stephen Tsang, MD, PhD headshot

Stephen Tsang, MD, PhD Professor of Ophthalmology and Professor of Pathology and Cell Biology, Columbia University Department of Pathology and Cell Biology New York, New York

Ajoy Vincent, MBBS, MS headshot

Ajoy Vincent, MBBS, MS Staff Ophthalmologist, Ophthalmology and Vision Sciences; Medical Director, Visual Electrophysiology Unit; Associate Scientist Genetics and Genome Biology Research Institute, The Hospital for Sick Children Toronto, Ontario, Canada

Michael Young, PhD, FARVO headshot

Michael Young, PhD, FARVO Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute; Director, Minda de Gunzburg Center for Retinal Regeneration, Harvard Medical School; Associate Scientist, Schepens Eye Research Institute of Massachusetts Eye and Ear Boston, Massachusetts

Chris Moen, MD headshot

Chris Moen, MD Chief Medical Officer, Choroideremia Research Foundation Medical Director, NaviHealth Wilmington, Delaware

Jess Thompson, MD

Jess Thompson, MD, MS Chair, Research Committee, Choroideremia Research Foundation Yavapai Cardiac Surgery Prescott, Arizona

Choroideremia Research Foundation logo icon in white

Join the CRF Science Advisory Board

If you are interested in joining our Science Advisory Board, please contact:
Dr. Chris Moen, Chief Medical Officer at (800) 201-0233 x 2 or for more information.


The search for a cure to CHM is not possible without our generous supporters.